Skip to main content
SpringerLink
Log in
Book cover

Thoracic Oncology pp 327–373Cite as

Malignant Pleural Mesothelioma

  • Chapter

Part of the book series: Cancer Treatment and Research ((CTAR,volume 105))

Abstract

Mesotheliomas are neoplasms originating from the thin layer of mesothelial cells lining the serosal surfaces of the pleural, pericardial and peritoneal cavities. This fact accounts for the otherwise curious reports of mesotheliomas arising from the tunica vaginalis testis (1), which represents a diverticular remnant of the peritoneum carried with the testes into the scrotum during their embryonic descent from the abdominal cavity. However, the vast majority of mesotheliomas (80%) originate within the pleural space (2), and this review will focus on recent advances in our understanding of malignant pleural mesotheliomas (MPMs) and on practical aspects of their management.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pias E, Riedl CR, Pflüger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer 83:2437–46, 1998.

    Article  Google Scholar 

  2. Benard F, Sterman D, Smith RJ, et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography [see comments]. Chest 114:713–22, 1998.

    Article  PubMed  CAS  Google Scholar 

  3. Klemperer P, Rabin CB. Primary neoplasms of the pleura: a report of five cases. Arch. Pathol. 11:385–412, 1931.

    Google Scholar 

  4. Nicholson W, Perkel G, Selikoff I. Occupational exposure to asbestos: population at risk and projected mortality: 1980–2030. Am. J. Ind. Med. 3:259–311, 1982.

    Article  PubMed  CAS  Google Scholar 

  5. Peto J, Decarli A, La Vecchia C, et al. The European mesothelioma epidemic. Br J Cancer 79:666–72, 1999.

    Article  PubMed  CAS  Google Scholar 

  6. Iwatsubo Y, Pairon JC, Boutin C, et al. Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study [see comments]. Am J Epidemiol 148:133–42, 1998.

    Article  PubMed  CAS  Google Scholar 

  7. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 14:466–480, 1996.

    Article  PubMed  CAS  Google Scholar 

  8. Camus M, Siemiatycki J, Meek B. Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer [see comments]. N Engl J Med 338:1565–71, 1998.

    Article  PubMed  CAS  Google Scholar 

  9. Rovia GC, Sartori F, Calabro F, et al. The association of pleural mesothelioma and tuberculosis. Am. Rev. Respir. Dis. 126:569–571, 1982.

    Google Scholar 

  10. Mossman BT, Gee JB. Asbestos-related diseases. N. Engl. J. Med. 320:1721–1730, 1989.

    Article  PubMed  CAS  Google Scholar 

  11. Bianchi C, Giarelli L, Grandi G, et al. Latency periods in asbestos-related mesothelioma of the pleura. Eur J Cancer Prey 6:162–6, 1997.

    CAS  Google Scholar 

  12. Smith TR. Malignant peritoneal mesothelioma: marked variability of CT findings. Abdom Imaging 19:27–9, 1994.

    Article  PubMed  Google Scholar 

  13. Grant DC, Seltzer SE, Antman KH, et al. Computed tomography of malignant pleural mesothelioma. J Comput Assist Tomogr 7:626–32, 1983.

    Article  PubMed  CAS  Google Scholar 

  14. Antman KH, Pass HI, Schiff PB. Benign and malignant mesothelioma, in DeVita VT, Hellman S, Rosenberg SA (eds): Cancer: principles and practice of oncology (ed 5th). Philadelphia, Lippincott-Raven, 1997, pp 1853–1878.

    Google Scholar 

  15. Weissmann LB, Corson JM, Neugut AI, et al. Malignant mesothelioma following treatment for Hodgkin’s disease. J Clin Oncol 14:2098–100, 1996.

    PubMed  CAS  Google Scholar 

  16. Mizuki M, Yukishige K, Abe Y, et al. A case of malignant pleural mesothelioma following exposure to atomic radiation in Nagasaki. Respirology 2:201–5, 1997.

    Article  PubMed  CAS  Google Scholar 

  17. Neugut AI, Ahsan H, Antman KH. Incidence of malignant pleural mesothelioma after thoracic radiotherapy. Cancer 80:948–50, 1997.

    Article  PubMed  CAS  Google Scholar 

  18. Strickler HD, Rosenberg PS, Devesa SS, et al. Contamination of poliovirus vaccines with simian virus 40 (1955–1963) and subsequent cancer rates [see comments]. Jama 279:292–5, 1998.

    Article  PubMed  CAS  Google Scholar 

  19. Olin P, Giesecke J. Potential exposure to SV40 in polio vaccines used in Sweden during 1957: no impact on cancer incidence rates 1960 to 1993. Dev Biol Stand 94:227–33, 1998.

    PubMed  CAS  Google Scholar 

  20. Galateau-Salle F, Bidet P, Iwatsubo Y, et al. SV40-like DNA sequences in pleural mesothelioma, bronchopulmonary carcinoma, and non-malignant pulmonary diseases. J Pathol 184:252–7, 1998.

    Article  PubMed  CAS  Google Scholar 

  21. Strickler HD, Goedert JJ, Fleming M, et al. Simian virus 40 and pleural mesothelioma in humans. Cancer Epidemiol Biomarkers Prey 5:473–5, 1996.

    CAS  Google Scholar 

  22. Procopio A, Marinacci R, Marinetti MR, et al. SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev Biol Stand 94:361–7, 1998.

    PubMed  CAS  Google Scholar 

  23. Carbone M, Pass HI, Rizzo P, et al. Simian virus 40-like DNA sequences in human pleural mesothelioma. Oncogene 9:1781–90, 1994.

    PubMed  CAS  Google Scholar 

  24. Pepper C, Jasani B, Navabi H, et al: Simian virus 40 large T antigen (SV40LTAg) primer specific DNA amplification in human pleural mesothelioma tissue. Thorax 51:1074–6, 1996.

    Article  PubMed  CAS  Google Scholar 

  25. Gibbs AR, Jasani B, Pepper C, et al. SV40 DNA sequences in mesotheliomas. Dev Biol Stand 94:41–5, 1998.

    PubMed  CAS  Google Scholar 

  26. Griffiths DJ, Nicholson AG, Weiss RA. Detection of SV40 sequences in human mesothelioma. Dev Biol Stand 94:127–36, 1998.

    PubMed  CAS  Google Scholar 

  27. Testa JR, Carbone M, Hirvonen A, et al. A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. Cancer Res 58:4505–9, 1998.

    PubMed  CAS  Google Scholar 

  28. Carbone M, Stach R, Di Resta I, et al. Simian virus 40 oncogenesis in hamsters. Dev Biol Stand 94:273–9, 1998.

    PubMed  CAS  Google Scholar 

  29. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy [see comments]. Chest 108:754–8, 1995.

    Article  PubMed  CAS  Google Scholar 

  30. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 107:332S–344S, 1995.

    Article  PubMed  CAS  Google Scholar 

  31. Steel TR, Allibone J, Revesz T, et al. Intradural neurotropic spread of malignant mesothelioma. Case report and review of the literature. J Neurosurg 88:122–5, 1998.

    Article  PubMed  CAS  Google Scholar 

  32. Prieto VG, Kenet BJ, Varghese M. Malignant mesothelioma metastatic to the skin, presenting as inflammatory carcinoma. Am J Dermatopathol 19:261–5, 1997.

    Article  PubMed  CAS  Google Scholar 

  33. Grellner W, Staak M: Multiple skeletal muscle metastases from malignant pleural mesothelioma. Pathol Res Pract 191:456–60; discussion 461–2, 1995.

    Google Scholar 

  34. Kubota K, Furuse K, Kawahara M, et al. A case of malignant pleural mesothelioma with metastasis to the orbit. Jpn J Clin Oncol 26:469–71, 1996.

    Article  PubMed  CAS  Google Scholar 

  35. Henderson DW, Shilkin KB, Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110:397–404, 1998.

    PubMed  CAS  Google Scholar 

  36. Boutin C, Loddenkemper R, Astoul P. Diagnostic and therapeutic thoracoscopy: techniques and indications in pulmonary medicine. Tuber. Lung Dis. 74:225–239, 1993.

    Article  CAS  Google Scholar 

  37. Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural needle biopsy in the diagnosis of malignant mesothelioma. J Comput Assist Tomogr 19:370–4, 1995.

    Article  PubMed  CAS  Google Scholar 

  38. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: Diagnosis. Cancer 72:389–93, 1993.

    Article  PubMed  CAS  Google Scholar 

  39. Kaiser L, Bavaria J. Complications of thoracoscopy. Ann. Thorac. Surg. 56:431–451, 1993.

    Google Scholar 

  40. Loddenkemper R. Thoracoscopy--state of the art. Eur Respir J 11:213–21, 1998.

    Article  PubMed  CAS  Google Scholar 

  41. Wilsher ML, Veale AG. Medical thoracoscopy in the diagnosis of unexplained pleural effusion. Respirology 3:77–80, 1998.

    Article  PubMed  CAS  Google Scholar 

  42. Maasilta P, Vehmas T, Kivisaari L, et al. Correlations between findings at computed tomography (CT) and at thoracoscopy/thoracotomy/autopsy in pleural mesothelioma. Eur Respir J 4:952–4, 1991.

    PubMed  CAS  Google Scholar 

  43. Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. AJR Am J Roentgenol 154:487–92, 1990.

    PubMed  CAS  Google Scholar 

  44. Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 96:171–7, 1988.

    PubMed  CAS  Google Scholar 

  45. McLoud TC. CT and MR in pleural disease. Clin Chest Med 19:261–76, 1998.

    Article  PubMed  CAS  Google Scholar 

  46. Falaschi F, Battolla L, Mascalchi M, et al. Usefulness of MR signal intensity in distinguishing benign from malignant pleural disease. AJR Am. J. Roentgenol. 166:963–968, 1996.

    PubMed  CAS  Google Scholar 

  47. Sugarbaker DJ, Strauss GM, Lynch Ti, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11:1172–8, 1993.

    PubMed  CAS  Google Scholar 

  48. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117:54–63; discussion 63–5, 1999.

    Article  PubMed  CAS  Google Scholar 

  49. Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111:815–25; discussion 825–6, 1996.

    Article  PubMed  CAS  Google Scholar 

  50. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 107:345S–350S, 1995.

    Article  PubMed  CAS  Google Scholar 

  51. Hillerdahl G. Malignant mesothelioma 1982: review of 4710 published cases. Br. J. Dis. Chest 77:321–343, 1983.

    Article  Google Scholar 

  52. Corson JM. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:347–55, 1997.

    PubMed  CAS  Google Scholar 

  53. Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its relationship to clinical parameters in patients with malignant pleural mesothelioma. Br J Cancer 77:907–12, 1998.

    Article  PubMed  CAS  Google Scholar 

  54. King JA, Tucker JA. Evaluation of membranous staining of mesothelioma. Cell Vis 5:24–7, 1998.

    PubMed  CAS  Google Scholar 

  55. Wolanski KD, Whitaker D, Shilkin KB, et al. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses. Cancer 82:583–90, 1998.

    Article  PubMed  CAS  Google Scholar 

  56. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma. Histopathology 31:140–3, 1997.

    Article  PubMed  CAS  Google Scholar 

  57. Ordóñez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma. Am J Surg Pathol22:1215–21, 1998.

    Article  PubMed  Google Scholar 

  58. Nagel H, Hemmerlein B, Ruschenburg I, et al. The value of anti-calretinin antibody in the differential diagnosis of normal and reactive mesothelia versus metastatic tumors in effusion cytology. Pathol Res Pract 194:759–64, 1998.

    Article  PubMed  CAS  Google Scholar 

  59. Ordóñez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod Pathol 11:929–33, 1998.

    PubMed  Google Scholar 

  60. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: a useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 32:209–16, 1998.

    Article  PubMed  CAS  Google Scholar 

  61. Di Loreto C, Puglisi F, Di Lauro V, et al. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 124:73–8, 1998.

    Article  PubMed  Google Scholar 

  62. Fetsch PA, Abati A, Hijazi YM. Utility of the antibodies CA 19–9, HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer 84:101–8, 1998.

    Article  PubMed  CAS  Google Scholar 

  63. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. Hum Pathol 29:166–9, 1998.

    Article  PubMed  Google Scholar 

  64. Ordonez NG. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature. Am J Clin Pathol 109:85–9, 1998.

    PubMed  CAS  Google Scholar 

  65. Oury TD, Hammar SP, Roggli VL. Ultrastructural features of diffuse malignant mesotheliomas. Hum Pathol 29:1382–92, 1998.

    Article  PubMed  CAS  Google Scholar 

  66. Warhol M, Hickey WF, Corson JM. Malignant mesothelioma: ultrastructural distinction from adenocarcinoma. Am. J. Surg. Pathol. 6:307–314, 1982.

    Article  PubMed  CAS  Google Scholar 

  67. Ross B, Motherby H, Saurenbach F, et al. Atomic force microscopy in effusion cytology. Anal Quant Cytol Histol 20:97–104, 1998.

    PubMed  CAS  Google Scholar 

  68. Suter M, Gebhard S, Boumghar M, et al. Localized fibrous tumours of the pleura: 15 new cases and review of the literature. Eur J Cardiothorac Surg 14:453–9, 1998.

    Article  PubMed  CAS  Google Scholar 

  69. Björkqvist AM, Tammilehto L, Nordling S, et al. Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. Br J Cancer 77:260–9, 1998.

    Article  PubMed  Google Scholar 

  70. Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma (review). Int J Oncol 14:181–8, 1999.

    Google Scholar 

  71. Prins JB, Williamson KA, Kamp MM, et al. The gene for the cyclin-dependentkinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 75:649–53, 1998.

    Article  PubMed  CAS  Google Scholar 

  72. Bianchi AB, Mitsunaga SI, Cheng JQ, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas [see comments]. Proc Natl Acad Sci U S A 92:10854–8, 1995.

    Article  PubMed  CAS  Google Scholar 

  73. Deguen B, Goutebroze L, Giovannini M, et al. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int J Cancer 77:554–60, 1998.

    Article  PubMed  CAS  Google Scholar 

  74. Balsara BR, Bell DW, Sonoda G, et al. Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15g11. 115 in human malignant mesothelioma. Cancer Res 59:450–4, 1999.

    PubMed  CAS  Google Scholar 

  75. Motherby H, Marcy T, Hecker M, et al. Static DNA cytometry as a diagnostic aid in effusion cytology: I. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes. Anal Quant Cytol Histol 20:153–61, 1998.

    PubMed  CAS  Google Scholar 

  76. Motherby H, Nadjari B, Remmerbach T, et al. Static DNA cytometry as a diagnostic aid in effusion cytology: II. DNA aneuploidy for identification of neoplastic cells in equivocal effusions. Anal Quant Cytol Histol 20:162–8, 1998.

    PubMed  CAS  Google Scholar 

  77. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 31:15–24, 1976.

    Article  PubMed  CAS  Google Scholar 

  78. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: Prognosis and staging. Cancer 72:394–404, 1993.

    Article  PubMed  CAS  Google Scholar 

  79. Mattson K. Natural history and clinical staging of malignant mesothelioma. Eur. J. Respir. Dis. 63:87 (abstract), 1982.

    Google Scholar 

  80. Chahinian AP. Therapeutic modalities in malignant pleural mesothelioma, in Chretien J, Hirsch A (eds): Diseases of the Pleura. New York, Masson, 1983, pp 224–236.

    Google Scholar 

  81. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group [see comments]. Chest 108:1122–8, 1995.

    Article  PubMed  CAS  Google Scholar 

  82. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer 14:1–12, 1996.

    Article  PubMed  CAS  Google Scholar 

  83. Mew D, Pass HI. Malignant mesotheliomas: a clinical challenge. Contemp Oncol:50–54, 62, 63, 66, 67, 1993.

    Google Scholar 

  84. Pass HI, Temeck BK, Kranda K, et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115:310–7; discussion 317–8, 1998.

    Google Scholar 

  85. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16:145–52, 1998.

    PubMed  CAS  Google Scholar 

  86. Gottehrer A, Taryle DA, Reed CE, et al. Pleural fluid analysis in malignant mesothelioma. Prognostic implications. Chest 100:1003–6, 1991.

    Article  PubMed  CAS  Google Scholar 

  87. Beer TW, Buchanan R, Matthews AW, et al. Prognosis in malignant mesothelioma related to MIB 1 proliferation index and histological subtype. Hum Pathol 29:246–51, 1998.

    Article  PubMed  CAS  Google Scholar 

  88. Bethwaite PB, Delahunt B, Holloway LJ, et al. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma. Pathology 27:1–4, 1995.

    Article  PubMed  CAS  Google Scholar 

  89. Isobe H, Sridhar KS, Doria R, et al. Prognostic significance of DNA aneuploidy in diffuse malignant mesothelioma. Cytometry 19:86–91, 1995.

    Article  PubMed  CAS  Google Scholar 

  90. Dazzi H, Thatcher N, Hasleton PS, et al. DNA analysis by flow cytometry in malignant pleural mesothelioma: relationship to histology and survival. J Pathol 162:51–5, 1990.

    Article  PubMed  CAS  Google Scholar 

  91. Pyrhonen S, Laasonen A, Lammilehto L, et al. Diploid predominance and prognostic significance of S-phase cells in malignant mesothelioma. Eur J Cancer 27:197, 1991.

    Article  PubMed  CAS  Google Scholar 

  92. Kumar Singh S, Vermeulen PB, Weyler J, et al. Evaluation of tumour angiogenesis as a prognostic marker in malignant mesothelioma. J Pathol 182:211–6, 1997.

    Article  PubMed  CAS  Google Scholar 

  93. Carmichael J, Degraff WG, Gamson J, et al. Radiation sensitivity of human lung cancer cell lines. Eur. J. Cancer Clin. Oncol. 25:527, 1989.

    Article  PubMed  CAS  Google Scholar 

  94. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 20:433–8, 1991.

    Article  PubMed  CAS  Google Scholar 

  95. Ball DL, Druickhawk DG. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience with special reference to radiotherapy. J. Clin. Oncol. 13:4–9, 1990.

    Article  CAS  Google Scholar 

  96. Gordon W, Antman K, Breenberger J, et al: Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 8:19, 1982.

    Article  PubMed  Google Scholar 

  97. de Graaf Strukowska L, van der Zee J, van Putten W, et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys 43:511–6, 1999.

    Article  PubMed  Google Scholar 

  98. Lindén CJ, Mercke C, Albrechtsson U, et al. Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study. Eur Respir J 9:2565–72, 1996.

    Article  PubMed  Google Scholar 

  99. Alberts AS, Falkson G, Goedhals L, et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6:527, 1988.

    PubMed  CAS  Google Scholar 

  100. Noppen M, Degreve J, Mignolet M, et al. A prospective, randomised study comparing the efficacy of talc slurry and bleomycin in the treatment of malignant pleural effusions. Acta Clin Belg 52:258–62, 1997.

    PubMed  CAS  Google Scholar 

  101. Martinez-Moragon E, Aparicio J, Rogado MC, et al. Pleurodesis in malignant pleural effusions: a randomized study of tetracycline versus bleomycin. Eur Respir J 10:2380–3, 1997.

    Article  PubMed  CAS  Google Scholar 

  102. Patz EF Jr, McAdams HP, Erasmus JJ, et al. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest 113:1305–11, 1998.

    Article  PubMed  CAS  Google Scholar 

  103. Yim AP, Chan AT, Lee TW, et al. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 62:1655–8, 1996.

    Article  PubMed  CAS  Google Scholar 

  104. Viallat JR, Rey F, Astoul P, et al. Thoracoscopic talc poudrage pleurodesis for malignant effusions. A review of 360 cases. Chest 110:1387–93, 1996.

    Article  PubMed  CAS  Google Scholar 

  105. Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:367–72, 1997.

    PubMed  CAS  Google Scholar 

  106. Sugarbaker DJ, Richards WG, Garcia JP. Extrapleural pneumonectomy for malignant mesothelioma. Adv Surg 31:253–71, 1997.

    PubMed  CAS  Google Scholar 

  107. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 14:1007–17, 1996.

    PubMed  CAS  Google Scholar 

  108. Taub RN, Antman KH. Chemotherapy for malignant mesothelioma. Semin Thorac Cardiovasc Surg 9:361–6, 1997.

    PubMed  CAS  Google Scholar 

  109. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 113:66S–73S, 1998.

    Google Scholar 

  110. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine (Gemzar) may reduce tumor load and tumor-associated symptoms in malignant pleural mesothelioma [abstract 1784], Proc. Am. Soc. Clin. Oncol. Los Angeles, CA, 1998, pp 464.

    Google Scholar 

  111. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 69:1431–2, 1985.

    PubMed  CAS  Google Scholar 

  112. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 11:1559–65, 1993.

    PubMed  CAS  Google Scholar 

  113. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 79:1897–902, 1997.

    Article  PubMed  CAS  Google Scholar 

  114. Middleton GW, Smith IE, ME OB, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 9:269–73, 1998.

    Article  PubMed  CAS  Google Scholar 

  115. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J. Clin. Oncol. 17:25–30, 1999.

    PubMed  CAS  Google Scholar 

  116. Rusch VW, Niedzwiecki D, Tao Y, et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10:1001–6, 1992.

    PubMed  CAS  Google Scholar 

  117. Lee JD, Perez S, Wang HJ, et al. Intrapleural chemotherapy for patients with incompletely resected malignant mesothelioma: the UCLA experience. J Surg Oncol 60:262–7, 1995.

    Article  Google Scholar 

  118. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74:24607, 1994.

    Article  Google Scholar 

  119. Perez-Soler R, Walsh GL, Swisher SG, et al. Phase II study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally in patients (PTS) with malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 18:#1626, 1999.

    Google Scholar 

  120. Sinoff C, Falkson G, Sandison AG, et al. Combined doxorubicin and radiation therapy in malignant pleural mesothelioma. Cancer Treat. Rep. 66:1605–1607, 1982.

    CAS  Google Scholar 

  121. Herscher LL, Hahn SM, Kroog G, et al. Phase I study of paclitaxel as a radiation sensitizer in the treatment of mesothelioma and non-small-cell lung cancer. J Clin Oncol 16:635–41, 1998.

    PubMed  CAS  Google Scholar 

  122. Baldini EH, Recht A, Strauss GM, et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63:334–8, 1997.

    Article  PubMed  CAS  Google Scholar 

  123. Rusch V, Saltz L, Venkatraman E, et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol 12:1156–63, 1994.

    PubMed  CAS  Google Scholar 

  124. Rice TW, Adelstein DJ, Kirby TJ, et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 58:24–9, 1994.

    Article  PubMed  CAS  Google Scholar 

  125. Pass HW, Temeck BK, Kranda K, et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2:214–20, 1995.

    Article  PubMed  CAS  Google Scholar 

  126. Myerson RI, Moros E, Roti Roti JL. Hyperthermia, in Perez CA, Brady LW (eds): Principles and practice of radiation oncology (ed 3rd). Philadelphia, Lippincott-Raven Publishers, Inc., 1997, pp 637–683.

    Google Scholar 

  127. Elias D, Gachot B, Bonvallot S, et al. [Peritoneal carcinosis treated by complete excision and immediate postoperative intra-peritoneal chemotherapy. Phase II study in 54 patients]. Gastroenterol Clin Biol 21:181–7, 1997.

    CAS  Google Scholar 

  128. Los G, van Vugt MJ, Pinedo HM. Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin. Br J Cancer 69:235–41, 1994.

    Article  PubMed  CAS  Google Scholar 

  129. van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 34:148–54, 1998.

    Article  PubMed  Google Scholar 

  130. Kuroda M, Urano M, Nishimura Y, et al. Induction thermochemotherapy increases therapeutic gain factor for the fractionated radiotherapy given to a mouse fibrosarcoma. Int J Radiat Oncol Biol Phys 38:411–7, 1997.

    Article  PubMed  CAS  Google Scholar 

  131. Jacquet P, Averbach A, Stuart OA, et al. Hyperthermic intraperitoneal doxorubicin: pharmacokinetics, metabolism, and tissue distribution in a rat model. Cancer Chemother Pharmacol 41:147–54, 1998.

    Article  PubMed  CAS  Google Scholar 

  132. Matsuzaki Y, Shibata K, Yoshioka M, et al. Intrapleural perfusion hyperthermochemotherapy for malignant pleural dissemination and effusion. Ann Thorac Surg 59:127–31, 1995.

    Article  PubMed  CAS  Google Scholar 

  133. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3:174–9, 1997.

    PubMed  CAS  Google Scholar 

  134. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal thermochemotherapy for prevention ofperitoneal recurrence of gastric cancer. Final results of a randomized controlled study. Cancer 73:2048–52, 1994.

    Article  PubMed  CAS  Google Scholar 

  135. Fujimoto S, Takahashi M, Mutou T, et al. Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgery. Cancer 79:884–91, 1997.

    Article  PubMed  CAS  Google Scholar 

  136. Jacquet P, Stephens AD, Averbach AM, et al. Analysis of morbidity and mortality in 60 patients with peritoneal carcinomatosis treated by cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy. Cancer 77:26229, 1996.

    Article  Google Scholar 

  137. Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Oncol 66:19–23, 1997.

    Article  PubMed  CAS  Google Scholar 

  138. Pelton JJ, Kowalyshyn MJ, Keller SM. Intrathoracic organ injury associated with photodynamic therapy. J Thorac Cardiovasc Surg 103:1218–23, 1992.

    PubMed  CAS  Google Scholar 

  139. Tochner ZA, Pass HI, Smith PD, et al. Intrathoracic photodynamic therapy: a canine normal tissue tolerance study and early clinical experience. Lasers Surg Med 14:118–23, 1994.

    Article  PubMed  CAS  Google Scholar 

  140. Pass HI, Pogrebniak H. Photodynamic therapy for thoracic malignancies. Semin Surg Oncol 8:217–25, 1992.

    Article  PubMed  CAS  Google Scholar 

  141. Luketich JD, Westkaemper J, Sommers KE, et al. Bronchoesophagopleural fistula after photodynamic therapy for malignant mesothelioma. Ann Thorac Surg 62:283–4, 1996.

    Article  PubMed  CAS  Google Scholar 

  142. Pass HI, Temeck BK, Kranda K, et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 4:628–33, 1997.

    Article  PubMed  CAS  Google Scholar 

  143. Pass HI, Donington JS. Use of photodynamic therapy for the management of pleural malignancies. Semin Surg Oncol 11:360–7, 1995.

    Article  PubMed  CAS  Google Scholar 

  144. Moskal TL, Dougherty TJ, Urschel JD, et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann Thorac Surg 66:112–833, 1998.

    Article  Google Scholar 

  145. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Patho-and immunobiology of malignant mesothelioma: characterization of tumor-infiltrating leukocytes and cytokine production in a murine model. Cancer Immunol Immunother 39:347–359, 1994.

    Article  PubMed  CAS  Google Scholar 

  146. Casciari JJ, Sato H, Dumm SK, et al. Tabular lexicon of cytokine structure and function, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy (ed 2nd). Philadelphia, Lippincott-Raven Publishers, 1996, pp 787–810.

    Google Scholar 

  147. Jagirdar J, Lee TC, Reibman J, et al. Immunohistochemical localization of transforming growth factor beta isoforms in asbestos-related diseases. Environ Health Perspect 105 Supp15:1197–203, 1997.

    Google Scholar 

  148. Maeda J, Ueki N, Ohkawa T, et al. Transforming growth factor-beta 1 (TGF-beta 1)- and beta 2-like activities in malignant pleural effusions caused by malignant mesothelioma or primary lung cancer. Clin Exp Immunol 98:319–22, 1994.

    Article  PubMed  CAS  Google Scholar 

  149. Schmitter D, Lauber B, Fagg B, et al. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51:296–301, 1992.

    Article  PubMed  CAS  Google Scholar 

  150. Monti G, Jaurand MC, Monnet I, et al. Intrapleural production of interleukin 6 during mesothelioma and its modulation by gamma-interferon treatment. Cancer Res 54:4419–23, 1994.

    PubMed  CAS  Google Scholar 

  151. Garlepp MJ, Leong CC. Biological and immunological aspects of malignant mesothelioma. Eur Respir J 8:643–50, 1995.

    PubMed  CAS  Google Scholar 

  152. Witt PL, Lindner DJ, D’Cunha J, et al. Pharmacology of interferons: induced proteins, cell activation, and antitumor activity, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy (ed 2nd). Philadelphia, Lippincott-Raven Publishers, 1996, pp 585–607.

    Google Scholar 

  153. Ohnuma T, Szrajer L, Holland JF, et al. Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice. Cancer Immunol Immunother 36:31–6, 1993.

    Article  PubMed  CAS  Google Scholar 

  154. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, et al. Potential for interferonalpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 15:213–23, 1995.

    Article  PubMed  CAS  Google Scholar 

  155. Ardizzoni A, Pennucci MC, Castagneto B, et al. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma. Am J Clin Oncol 17:80–2, 1994.

    Article  PubMed  CAS  Google Scholar 

  156. Christmas TI, Manning LS, Garlepp MJ, et al. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:9–12, 1993.

    Article  PubMed  CAS  Google Scholar 

  157. Von Hoff DD, Metch B, Lucas JG, et al. Phase II evaluation of recombinant interferon-beta (IFN-beta ser) in patients with diffuse mesothelioma: a Southwest Oncology Group study. J Interferon Res 10:531–4, 1990.

    Article  Google Scholar 

  158. Rosso R, Rimoldi R, Salvati F, et al. Intrapleural natural beta interferon in the treatment of malignant pleural effusions. Oncology 45:253–6, 1988.

    Article  PubMed  CAS  Google Scholar 

  159. Zeng L, Buard A, Monnet I, et al. In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines. Int J Cancer 55:515–20, 1993.

    Article  PubMed  CAS  Google Scholar 

  160. Hasturk S, Tastepe I, Unlu M, et al. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 8:159–64, 1996.

    PubMed  CAS  Google Scholar 

  161. Hand A, Pelin K, Mattson K, et al. Interferon (IFN)-alpha and IFN-gamma in combination with methotrexate: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 6:77–82, 1995.

    Article  PubMed  CAS  Google Scholar 

  162. Hand AM, Husgafvel-Pursiainen K, Pelin K, et al. Interferon-alpha and -gamma in combination with chemotherapeutic drugs: in vitro sensitivity studies in four human mesothelioma cell lines. Anticancer Drugs 3:687–94, 1992.

    Article  PubMed  CAS  Google Scholar 

  163. Sklarin NT, Chahinian AP, Feuer EJ, et al. Augmentation of activity of cisdiamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice. Cancer Res 48:64–7, 1988.

    PubMed  CAS  Google Scholar 

  164. Soulie P, Ruffle P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 14:878–85, 1996.

    PubMed  CAS  Google Scholar 

  165. Manning LS, Bowman RV, Darby SB, et al. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine-activated killer (LAK) cells. Am Rev Respir Dis 139:1369–74, 1989.

    PubMed  CAS  Google Scholar 

  166. Goey SH, Eggermont AM, Punt CJ, et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 72:1283–8, 1995.

    Article  PubMed  CAS  Google Scholar 

  167. Astoul P, Picat Joossen D, Viallat JR, et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 83:2099–104, 1998.

    Article  PubMed  CAS  Google Scholar 

  168. Astoul P, Bertault-Peres P, Durand A, et al. Pharmacokinetics of intrapleural recombinant interleukin-2 in immunotherapy for malignant pleural effusion. Cancer 73:308–13, 1994.

    Article  PubMed  CAS  Google Scholar 

  169. Lissoni P, Barni S, Tancini G, et al. Intracavitary therapy of neoplastic effusions with cytokines: comparison among interferon alpha, beta and interleukin-2. Support Care Cancer 3:78–80, 1995.

    Article  PubMed  CAS  Google Scholar 

  170. Curiel DT, Pilewski JM, Albelda SM. Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol 14:1–18, 1996.

    Article  PubMed  CAS  Google Scholar 

  171. Sterman DH, Kaiser LR, Albelda SM. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12:553–68, 1998.

    Article  PubMed  CAS  Google Scholar 

  172. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the ‘bystander effect’ of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3:85–92, 1996.

    PubMed  CAS  Google Scholar 

  173. Russell SJ, Eccles SA, Flemming C, et al. Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer 47:244, 1991.

    Article  PubMed  CAS  Google Scholar 

  174. Batra RK, Olsen JC, Pickles RJ, et al. Transduction of non-small cell lung cancer cells by adenoviral and retroviral vectors. Am J Respir Cell Mol Biol 18:402–10, 1998.

    PubMed  CAS  Google Scholar 

  175. Frizelle SP, Grim J, Zhou J, et al. Re-expression of p l6INK4a in mesothelioma cells results in cell cycle arrest, cell death, tumor suppression and tumor regression. Oncogene 16:3087–95, 1998.

    Article  PubMed  CAS  Google Scholar 

  176. Procopio A, Strizzi L, Giuffrida A, et al. Human malignant mesothelioma of the pleura: new perspectives for diagnosis and therapy. Monaldi Arch Chest Dis 53:241–3, 1998.

    PubMed  CAS  Google Scholar 

  177. Robinson BW, Mukherjee SA, Davidson A, et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J Immunother 21:211–7, 1998.

    Article  PubMed  CAS  Google Scholar 

  178. Elshami AA, Kucharczuk JC, Sterman DH, et al. The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 222:298–307; 307–10, 1995.

    Google Scholar 

  179. Elshami AA, Kucharczuk JC, Zhang HB, et al. Treatment of pleural mesothelioma in an immunocompetent rat model utilizing adenoviral transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7:141–8, 1996.

    Article  PubMed  CAS  Google Scholar 

  180. Smythe WR, Hwang HC, Amin KM, et al. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system. Cancer Res 54:2055–9, 1994.

    PubMed  CAS  Google Scholar 

  181. Esandi MC, van Someren GD, Vincent AJ, et al. Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 4:280–7, 1997.

    Article  PubMed  CAS  Google Scholar 

  182. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg 222:78–86, 1995.

    Article  PubMed  CAS  Google Scholar 

  183. Schwarzenberger P, Lei D, Freeman SM, et al. Antitumor activity with the HSVtk-gene-modified cell line PA-I-STK in malignant mesothelioma. Am J Respir Cell Mol Biol 19:333–7, 1998.

    PubMed  CAS  Google Scholar 

  184. Yang CT, You L, Yeh CC, et al. Adenovirus-mediated p14“RFgene transfer I in human mesothelioma cells. J Natl Cancer Inst 92:636–41, 2000.

    Article  PubMed  CAS  Google Scholar 

  185. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 13:716, 1995.

    Google Scholar 

  186. Kucharczuk JC, Elshami AA, Zhang HB, et al. Pleural-based mesothelioma in immune competent rats: a model to study adenoviral gene transfer. Ann Thorac Surg 60:593–7; discussion 597–8, 1995.

    Google Scholar 

  187. Kaiser LR. New therapies in the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9:383–90, 1997.

    PubMed  CAS  Google Scholar 

  188. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9:1083–92, 1998.

    Article  PubMed  CAS  Google Scholar 

  189. Musk AW, de Klerk NH, Ambrosini GL, et al. Vitamin A and cancer prevention I: observations in workers previously exposed to asbestos at Wittenoom, Western Australia. Int J Cancer 75:355–61, 1998.

    Article  PubMed  CAS  Google Scholar 

  190. de Klerk NH, Musk AW, Ambrosini GL, et al. Vitamin A and cancer preventionII: comparison of the effects of retinol and beta-carotene. Int J Cancer 75:362–7, 1998.

    Article  PubMed  Google Scholar 

  191. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease [see comments]. N Engl J Med 334:1150–5, 1996.

    Article  PubMed  CAS  Google Scholar 

  192. Omenn GS, Goodman G, Thornquist M, et al. The I3-Carotene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer in high-risk populations: smokers and asbestos-exposed workers. Cancer Res. 54:2038–2043, 1994.

    Google Scholar 

  193. Goodman GE, Thornquist M, Kestin M, et al. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha- Tocopherol, Beta Carotene Cancer Prevention Study Group [see comments]. N Engl J Med 330:1029–35, 1994.

    Article  Google Scholar 

  194. Harmon D, Vogelzang NJ, Roboz J, et al. Dihydro-5-azacytidine (DHAC) in malignant mesothelioma (Meso) using secrum hyaluronic acid (SHA) as a tumor marker: a phase II trial of the CALGB [abstract 1248], Proc Am Soc Clin Oncol pp 351, 1991.

    Google Scholar 

  195. Cantwell BMJ, Earnshaw M, Harris AL, et al. Phase II study of a novel antifolate, N10-propargyl-5,8-dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 70:1335–1336, 1986.

    PubMed  CAS  Google Scholar 

  196. Belani CP, Herndon J, Vogelzang NJ, et al. Edatrexate with oral leucovorin rescue for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B-CALGB 9131 [abstract 1068]., Proc. Am. Soc. Clin. Oncol pp 352, 1995.

    Google Scholar 

  197. Harvey VJ, Slevin ML, Ponder BAJ, et al. Chemotherapy of diffuse malignant mesothelioma: phase II trials of single agent 5-fluorouracil and adriamycin. Cancer 54:961–964, 1984.

    Article  PubMed  CAS  Google Scholar 

  198. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 65:956–60, 1992.

    Article  PubMed  CAS  Google Scholar 

  199. Vogelzang NJ, Weissman LB, Herndon JE, et al. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. J Clin Oncol 12:1436–42, 1994.

    PubMed  CAS  Google Scholar 

  200. Mbidde EK, Harland SJ, Cavert AH, et al. Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 18:284–285, 1986.

    CAS  Google Scholar 

  201. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 8:151–4, 1990.

    PubMed  CAS  Google Scholar 

  202. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother. Pharmacol. 27:239–242, 1990.

    CAS  Google Scholar 

  203. Mintzer DM, Kelsen D, Frimmer D, et al. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 69:711–712, 1985.

    CAS  Google Scholar 

  204. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest. New Drugs 6:223–226, 1988.

    CAS  Google Scholar 

  205. Falkson G, Vorobiof DA, Lerner JH, et al. A phase II study of M-AMSA in patients with malignant mesothelioma. Cancer Chemother. Pharmacol. 11:94–97, 1983.

    CAS  Google Scholar 

  206. Colbert N, Vannetzel JM, Izrael V. A prospective study of detorubicin in malignant pleural mesothelioma. Cancer 56:2170–2174, 1985.

    Article  PubMed  CAS  Google Scholar 

  207. Eagan R, Frytak S, Richardson R, et al. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 70:429, 1986.

    PubMed  CAS  Google Scholar 

  208. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma, the Eastern Cooperative Oncology Group (ECOG) experience. Cancer 52:1981–1985, 1983.

    Article  PubMed  CAS  Google Scholar 

  209. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. Tumori 77:49–51, 1991.

    PubMed  CAS  Google Scholar 

  210. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: a phase II study of th European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 10:824–828, 1992.

    PubMed  CAS  Google Scholar 

  211. Hudis CA, Kelsen DP. Menogaril in treatment of malignant mesothelioma: a phase II study. Invest. New Drugs 10:103–106, 1992.

    Article  CAS  Google Scholar 

  212. Eisenhauer EA, Evans WK, Raghavan D, et al. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group study. Cancer Treat. Rep. 70:1029–1030, 1986.

    CAS  Google Scholar 

  213. van Breukelen FJ, Mattson K, Giaccone G, et al. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 27:1627–9, 1991.

    Article  PubMed  Google Scholar 

  214. Sridhar KS, Doria R, Hussein AM, et al. Activity and toxicity of 4’-otetrahydropyranyladriamycin (pirarubicin) in malignant mesothelioma [abstract 1225], Proc. Am. Soc. Clin. Oncol., pp 356, 1992.

    Google Scholar 

  215. Kaukel E, Koschel G, Gatzemeyer U, et al. A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 66:651–4, 1990.

    Article  PubMed  CAS  Google Scholar 

  216. Alberts AS, Falkson G, Zyl LV. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J. Natl. Cancer Inst. 80:968–970, 1988.

    Article  Google Scholar 

  217. Falkson G, Hunt M, Borden EC, et al. An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma. Invest. New Drugs 10:337–343, 1992.

    Article  CAS  Google Scholar 

  218. Zidar BL, Metch B, Balcerzak SP, et al. A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma. A Southwest Oncology Group study. Cancer 70:2547–51, 1992.

    Article  PubMed  CAS  Google Scholar 

  219. Icli F, Karaoguz H, Dincol D, et al. A phase II study of ifosfamide (I) in unresectable diffuse malignant mesothelioma (MM) [abstract 1650], Proc. Am. Soc. Clin. Oncol., pp 472, 1993.

    Google Scholar 

  220. Bajorin D, Kelsen D, Mintzer DM. Phase II trial of mitomycin in malignant mesothelioma. Cancer Treat. Rep. 71:857–858, 1987.

    CAS  Google Scholar 

  221. Wasser L, Hunt M, Lerner H, et al. Phase II trial of PCNU in malignant mesothelioma: an ECOG trial, Proc. Am. Soc. Clin. Oncol., pp. 309, 1989.

    Google Scholar 

  222. Belani CP, Adak S, Aisner S, et al. Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group (ECOG 2595). Proc Am Soc Clin Oncol 18:#1829, 1999.

    Google Scholar 

  223. Tammilehto L, Maasilta P, Mantyla M, et al. Oral etoposide in the treatment of malignant mesothelioma. A phase II study. Ann Oncol 5:949–50, 1994.

    PubMed  CAS  Google Scholar 

  224. Vogelzang NJ, Herndon J, Clamon GH, et al. Paclitaxel (Taxol) for malignant mesothelioma (MM): a phase II study of the Cancer and Leukemia Group B (CALGB 9234) [abstract 1382], Proc. Am. Soc. Clin. Oncol., pp 405, 1994.

    Google Scholar 

  225. Maksymiuk AW, Marschke RF, Jr., Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 21:610–3, 1998.

    Article  PubMed  CAS  Google Scholar 

  226. Cowan JD, Green S, Lucas J, et al. Phase II trial of 5-day intravenous infusion of vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study [letter. Invest. New Drugs 6, 1988.

    Google Scholar 

  227. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma--a negative report. Cancer Chemother Pharmacol 24:133–4,1989.

    Article  PubMed  CAS  Google Scholar 

  228. Kelsen D, Gralla R, Cheng E, et al. Vindesine in the treatment of malignant mesothelioma: a phase II study. Cancer Treat. Rep. 67:821–822, 1983.

    CAS  Google Scholar 

  229. Boutin C, Irisson M, Guerin JC, et al. Phase II trial of vindesine in malignant pleural mesothelioma. Cancer Treat. Rep. 71:205–206, 1987.

    CAS  Google Scholar 

  230. Steele JPC, Evans MT, Tischkowitz MD, et al. Vinorelbine is an active and well-tolerated drug for the treatment of malignant mesothelioma: a phase II study. Proc Am Soc Clin Oncol 18:#1891, 1999.

    Google Scholar 

  231. Webster I, Cochrane JWC, Burkhardt KR, et al. Immunotherapy with BCG in 30 cases of mesothelioma. S. Afr. Med. J. 61:277–278, 1982.

    PubMed  CAS  Google Scholar 

  232. Costanzi J, Darzynkiewicz Z, Chun H, et al. The use of Onconase (ONC) for patients (PTS) with advanced malignant mesothelioma (MM) [abstract 1414], Proc. Am. Soc. Clin. Oncol., pp 452, 1996.

    Google Scholar 

  233. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 96:746–55, 1982.

    PubMed  CAS  Google Scholar 

  234. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 67:2984–7, 1991.

    Article  PubMed  CAS  Google Scholar 

  235. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma [see comments]. Cancer 76:2230–6, 1995.

    Article  PubMed  CAS  Google Scholar 

  236. Pronzato P, Ardizzoni A, Pennucci MC, et al. Phase II FONICAP trial with cisplatin, doxorubicin, and mitomycin for advanced pleural mesothelioma patients [abstract 1209], Proc. Am. Soc. Clin. Oncol., pp 398, 1991.

    Google Scholar 

  237. Breau JL, Boaziz C, Morere JJF, et al. Combination chemotherapy with cisplatinum, Adriamycin, bleomycin, and mitomycin C plus systemic and intrapleural hyaluronidase in 25 consecutive cases of stage II and III pleural mesothelioma, First International Mesothelioma Conference. Paris, France, 1991.

    Google Scholar 

  238. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 5:86–91, 1987.

    PubMed  CAS  Google Scholar 

  239. Dhingra H, Valdivieso M, Tannir N, et al. Combined modality treatment for mesothelioma with Cytoxan, Adriamycin, and DTIC (CYADIC) and adjuvant surgery [abstract C-800], Proc. Am. Soc. Clin. Oncol., pp 205, 1983.

    Google Scholar 

  240. Carmichael J, Cantwell BM, Harris AL. A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma [see comments]. Eur J Cancer Clin Oncol 25:911–2, 1989.

    Article  PubMed  CAS  Google Scholar 

  241. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 5:653–5, 1994.

    PubMed  CAS  Google Scholar 

  242. Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 23:683–7, 1993.

    Article  PubMed  CAS  Google Scholar 

  243. Samuels BL, Herndon JE, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 82:1578–84, 1998.

    Article  PubMed  CAS  Google Scholar 

  244. Eisenhauer EA, Evans WK, Murray N, et al. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma: an NCI Canada Clinical Trials Group study. Invest. New Drugs 6:327–329, 1988.

    CAS  Google Scholar 

  245. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 6:613–5, 1995.

    PubMed  CAS  Google Scholar 

  246. Pogrebniak H, Kranda K, Steinberg S, et al. Cisplatin, interferon-a, and tamoxifen (CIT) for malignant pleural mesothelioma [abstract 1363], Proc. Am. Soc. Clin. Oncol., pp 398, 1993.

    Google Scholar 

  247. Tansan S, Emri S, Selcuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 51:348–51, 1994.

    Article  PubMed  CAS  Google Scholar 

  248. Rodier JM, Couteau C, Ruffle P, et al. Phase II study of a monthly combination of cisplatin, mitomycin, and interferon-alfa in malignant pleural mesothelioma [abstract 1174], Proc Am Soc Clin Oncol, pp 390, 1996.

    Google Scholar 

  249. Koschel G, Calavrezos A, Kaukel E, et al. Phase III randomized comparison of pirarubicin vs. pirarubicin and cisplatin for treatment of pleural mesotheliomas [abstract 1097]. Eur J Cancer 27:S180, 1991.

    Google Scholar 

  250. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma [see comments]. Lung Cancer 11:299–303, 1994.

    Article  PubMed  CAS  Google Scholar 

  251. Ilson DH, Saltz L, Martin L, et al. A phase II trial of interferon alpha 2a (IFNa) and carboplatin in malignant mesothelioma [abstract], Proc. Am. Soc. Clin. Oncol., pp 456, 1996.

    Google Scholar 

  252. Magri MD, Foladore S, Veronis A, et al. Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II comparative study. Ann Oncol 2:237238, 1992.

    Google Scholar 

  253. Bretti S, Berruti A, Dogliotti L, et al. Combined epirubicin and interleukin-2 regimen in the treatment of malignant mesothelioma: a multicenter phase II study of the Italian Group on Rare Tumors. Tumori 84:558–61, 1998.

    PubMed  CAS  Google Scholar 

  254. Pinto C, Melotti B, Piana E, et al. Phase II study of mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant mesothelioma of the pleura. Proc Am Soc Clin Oncol 18:#2113, 1999.

    Google Scholar 

  255. Daniel C, Fizazi K, Fandi A, et al. ‘Tomudex’ (raltitrexed) and Eloxatine (oxaliplatin) is an active combination with acceptable toxicity in malignant mesothelioma. Proc Am Soc Clin Oncol 18:#1844, 1999.

    Google Scholar 

  256. Zidar BL, Benjamin RS, Frank J, et al. Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group study. Am J Clin Oncol 6:71–74, 1983.

    PubMed  CAS  Google Scholar 

  257. Rusch VW, Figlin R, Godwin D, et al. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9:313–9, 1991.

    PubMed  CAS  Google Scholar 

  258. Astoul P, Viallat JR, Laurent JC, et al. Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 103:209–13, 1993.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anderson Cancer Center, Houston, TX, 77030

    Linus Ho M.D., Ph. D.

  2. Brigham and Women’s Hospital, Boston, MA, 02115

    Sugarbaker J. David M.D.

  3. Dana-Farber Cancer Institute, Boston, MA, 02115

    Arthur T. Skarin M.D.

Authors
  1. Linus Ho M.D., Ph. D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sugarbaker J. David M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arthur T. Skarin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Baltimore, Maryland, USA

    David S. Ettinger MD

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Springer Science+Business Media New York

About this chapter

Cite this chapter

Ho, L., David, S.J., Skarin, A.T. (2001). Malignant Pleural Mesothelioma. In: Ettinger, D.S. (eds) Thoracic Oncology. Cancer Treatment and Research, vol 105. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1589-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-1589-0_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-5629-5

  • Online ISBN: 978-1-4615-1589-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation